Cambridge protein analysis technology boosted by US patent consent
Cambridge University spin-out Fluidic Analytics has won a key patent approval in the United States to accelerate protein analysis technology.
The startup specialises in the development of microfluidic technology for the rapid characterisation of native proteins in-solution based on their physical properties.
The application of its technology will provide information about proteins and their behaviour, transforming understanding of how the biological world operates, and will helpinform better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being.
The patent ‘Fluidic Separation and Detection’, has been granted by the United States Patent and Trademark Office. It paves the way for the development and commercialisation of a next-generation protein analysis technology platform to be launched later this year.
CEO Dr Andrew Lynn said: “The issuance of the US Patent for our fluidic separation and detection technology is key to building a platform that we believe will fundamentally change how scientists conduct protein analysis.
“The modular nature of microfluidics makes this technology a foundation on which we can build and support advanced analytical approaches, enabling native state proteins to be easily measured in the lab, clinic or even in the home.
“We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates. Securing the US Patent for our Fluidic Separation and Detection technology is an important step in making this vision a reality.
“We believe our products, starting with the Fluidity One, will help improve understanding of how proteins behave and inform better decisions about how diseases are diagnosed, treatments are developed and personal well-being is maintained.
“There is a need for technologies that can characterise proteins in their native state, quickly, and without complex workflows – and that is what we are creating.”
The patented Fluidic Separation and Detection technology is incorporated into the Fluidity One solution and combined with an intuitive Android™ based user interface, cloud computing capabilities and disposable microfluidic chips to ensure the best possible user experience.
Applications of the technology include the analysis of protein quality and understanding protein interactions and aggregation. These are important both in fundamental biological research, but also in the development of biopharmaceuticals, which now comprise as much as 50 per cent of all drugs in development.
•PHOTOGRAPH SHOWS: Andrew Lynn, CEO of Fluidic Analytics